150 related articles for article (PubMed ID: 23351371)
21. How to overcome antiviral-resistant hepatitis B virus?
Song BC
Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus and HIV infection.
Martín-Carbonero L; Poveda E
Semin Liver Dis; 2012 May; 32(2):114-9. PubMed ID: 22760650
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].
Hu AR; Jiang SW; Li L; Ding SX; Hu YR; Liang XY
Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(27):1878-81. PubMed ID: 23134956
[TBL] [Abstract][Full Text] [Related]
24. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
26. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
Fournier C; Zoulim F
Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
[TBL] [Abstract][Full Text] [Related]
27. Management of antiviral resistance in patients with chronic hepatitis B.
Locarnini S; Hatzakis A; Heathcote J; Keeffe EB; Liang TJ; Mutimer D; Pawlotsky JM; Zoulim F
Antivir Ther; 2004 Oct; 9(5):679-93. PubMed ID: 15535405
[TBL] [Abstract][Full Text] [Related]
28. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
Teo CG; Locarnini SA
Antivir Ther; 2010; 15(3 Pt B):445-9. PubMed ID: 20516564
[TBL] [Abstract][Full Text] [Related]
29. Life cycle synchronization is a viral drug resistance mechanism.
Neagu IA; Olejarz J; Freeman M; Rosenbloom DIS; Nowak MA; Hill AL
PLoS Comput Biol; 2018 Feb; 14(2):e1005947. PubMed ID: 29447150
[TBL] [Abstract][Full Text] [Related]
30. Pathobiology of HBV mutants and clinical impact for treatment monitoring.
Si Ahmed SN; Zoulim F
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):309-20. PubMed ID: 19344244
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
[TBL] [Abstract][Full Text] [Related]
32. Molecular genesis of drug-resistant and vaccine-escape HBV mutants.
Locarnini SA; Yuen L
Antivir Ther; 2010; 15(3 Pt B):451-61. PubMed ID: 20516565
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
35. Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials.
Sypsa V; Hatzakis A
Stat Med; 2008 Dec; 27(30):6505-21. PubMed ID: 18951370
[TBL] [Abstract][Full Text] [Related]
36. Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
Fischer KP; Gutfreund KS; Tyrrell DL
Drug Resist Updat; 2001 Apr; 4(2):118-28. PubMed ID: 11512520
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
38. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
Carrouée-Durantel S; Durantel D; Werle-Lapostolle B; Pichoud C; Naesens L; Neyts J; Trépo C; Zoulim F
Antivir Ther; 2008; 13(3):381-8. PubMed ID: 18572751
[TBL] [Abstract][Full Text] [Related]
39. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
40. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
